Advertisement

Topics

Companies Related to "Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection" [Most Relevant Company Matches] RSS

08:35 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection" found in our extensive corporate database of over 50,000 company records.

Showing "Efficacy Safety Study Plus Ribavirin Treat Chronic Hepatitis" Companies 1–25 of 3,700+

Relevant

SciClone Pharmaceuticals

SciClone is a global biopharmaceutical company that acquires, develops, and commercializes specialist-oriented drugs for treating chronic and life-threatening diseases, such as hepatitis B, hepatitis C, cancer, immune system disorders and cystic fibrosis.


TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, with a particular emphasis on antiviral drugs to treat diseases caused by hepatitis B and C viruses (HBV and HCV), HIV and herpes viruses.Product Candidate PortfolioThe Company’s broad drug developm...


Roche Biosciences

Today Roche Bioscience researchers are focused on the discovery and delivery of new medicines to treat the following diseases:Alzheimer's disease HIV/AIDS Arthritis Incontinence Asthma Osteoporosis Anxiety Overactive bladder Auto-immune disorders Benign prostatic hyperplasia Depression Pelvic hypersensitivity Emphysema and chronic bronchitis Schizophrenia Hepatitis C

Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian immunotherapeutics business created in April 2012 through the reverse takeover of Probiomics (ASX: PCC) by privately held Hunter Immunology. The Company’s lead therapy, HI-164OV is based on the Company’s proprietary technology that uses the application of mucosal immunology to treat common human diseases.  HI-164OV, in Phase IIb clinica...

Illumigen Biosciences, Inc.

Illumigen Biosciences, Inc. is the market leader in the use of proprietary genetic technologies to identify naturally occurring health-inducing mutations. These beneficial mutations provide a rapid method for developing novel drugs with improved efficacy and fewer side effects. Illumigen is using its technologies to develop drugs to treat hepatitis C infection, obesity, and other diseases. To find...

Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulat...

Hepatitis B Foundation

The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. Visit www.hepb.org.

World Hepatitis Alliance

The following people have provided quotes expressing their support to the World Hepatitis Alliance campaign for a WHO resolution on viral hepatitis. For further information please contact worldhepday@fleishman.com

CMI - Centers for Medical Innovation AG

CMI AG is a bioscience company that is engaged in the identification, development and commercialization of a new generation of plant derived prescription drugs for the treatment of serious chronic diseases such as chronic hepatitis B and C, Parkinsons Disease. CMI AG first began operations in Ocotber 1997 and has currently two plant products in development. Exclusive Options on two more promising ...

Aethlon Medical, Inc

Aethlon Medical is a publicly traded company based in San Diego, California. Since June of 2001, the sole focus of the company has been the development of a broad spectrum viral and toxin treatment device known as Hemopurifier™. During this period, Aethlon researchers have evolved the Hemopurifier from a conceptual device to a product now being manufactured and tested for safety in human clinica...

World of Health Biotech Co.Ltd

Anti HBV Specific Active Immunotherapy (Anti HBV Therapeutic Vaccine) using recombinant hepatitis B vaccine (standard HBV vaccine) as an immunogenic specific antigen and several cytokines as an immune adjuvant is a new antiviral approach for chronic HBV infection. The first and most critical setp in the design of an anti HBV therapeutic vaccine is the selection of the specific antigens that will b...

Madaus AG

As an international phytopharmaceutical company, Madaus AG has developed and currently manufactures highly effective medicines of plant origin together with health-promoting products for "Natural Prevention". The objective of all products of Madaus is to treat the fundamental causes of disease, not merely the symptoms, and thereby to prevent diseases from occurring or at least from becoming chroni...

Afferent Pharmaceuticals

Afferent Pharmaceuticals is focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. Research shows that P2X3-containing receptors are highly specific to nerve fibers that transmit the sensations of pain and discomfort in response to inflammation or injury, particularly in chronic conditions. P2X3...

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. Novelos is seeking to build a pipeline through licensing or acquiring clinical stage compounds or technologies for oncology indications. Our lead compound, NOV-002, has been administered to approximately ...

Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions. The Company's most popular product is its Xin-Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to...

SanBio Co., Ltd.

SanBio (TOKYO:4592) is a leading regenerative medical products company headquartered in Tokyo and Mountain View, California, with cell-based products in various stages of research, development and clinical trials. The company has completed enrollment for and is conducting a Phase 2b clinical trial for its proprietary regenerative medical product SB623 for ...

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nuc...

Ascendant Neuro

For the past 15 years, Ascendant Neuro has successfully conducted minimally invasive pain treatment techniques through the innovative use of neurostimulators. Ascendant Neuro's trained physicians, which treat chronic pain of the spine as well as chronic migraine headaches, use neurostimulation to eliminate the symptoms of migraine and chronic head pain.

AtheroGenics Incorporated

AtheroGenics is an emerging pharmaceutical company focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, such as atherosclerosis, rheumatoid arthritis and asthma. AtheroGenics has cultivated a drug discovery and development capability directed toward rapidly creating and transporting small molecule therapeutics into the clini...

iQur Ltd

iQur® is a specialty pharmaceutical company at the forefront of international breakthroughs in the detection, treatment and monitoring of Hepatitis C and other liver diseases.iQur exists to provide clinicians with a comprehensive, 24–48 hour service for genotyping, qualitation and quantification of both the Hepatitis C (HCV) and Hepatitis B (HBV) viruses.Founded in 2003 by liver disease special...

Coeur Scientific Inc.

Coeur Scientific Inc. is a contract development company committed to providing expert consultations and complete in vivo, in vitro preclinical study management in a state-of-the-art professional environment. These services produce detailed and thorough information on the efficacy and safety of new medical devices, procedures and therapeutic agents. Our primary objective is to deliver quality dat...

Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistami...

NeuroTherapeutics Pharma, Inc.

NeuroTherapeutics Pharma is a privately held life sciences company which is focused on the discovery and development of novel therapeutics for patients suffering from CNS disorders. The company is developing compounds that decrease or eliminate aberrant excitatory discharges by working through a new mechanism of action which is unlike that of any marketed ...

Oxxon Pharmaccines Limited

Oxxon Pharmaccines™ Ltd is a biotechnology company developing novel pharmaccines (therapeutic vaccines) based on its unique PrimeBoost technologies for the treatment of chronic infectious diseases and cancer. We currently have products in clinical trials for the treatment of melanoma and hepatitis B virus, and our founding collaborators have ongoing clinical programmes developing preventative va...


More From BioPortfolio on "Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks